Cancer Prevention Pharmaceuticals

General Information

We are a clinical-stage biopharmaceutical company formed primarily to develop and commercialize therapeutic agents for the treatment and prevention of certain pre-cancerous conditions, orphan diseases (i.e., rare diseases) and gastrointestinal conditions. We are currently enrolling patients in our Phase 3 clinical trial with our product candidate CPP-1X/sul for the treatment of familial adenomatous polyposis (“FAP”), a rare inherited condition that can cause the growth of thousands of colorectal adenomas (i.e., adenomatous polyps), which are recognized as a key risk factor for colon cancer, and we are a regulatory and commercial collaborator in a Phase 3 clinical trial funded by the National Cancer Institute (the “NCI”) for the study of colon cancer risk reduction and colon adenoma therapy (“CAT”), a preventative treatment approach for survivors of colorectal cancer or those who have high-risk colon polyps

Employees: 10
Founded: 2009
Contact Information
Address 1760 East River Road, Suite 250, Tucson, AZ 85718, US
Phone Number (520) 908-7774
Web Address
View Prospectus: Cancer Prevention Pharmaceuticals
Financial Information
Market Cap $87.9mil
Revenues $3.7 mil (last 12 months)
Net Income $-5.7 mil (last 12 months)
IPO Profile
Symbol CPP
Exchange NYSE
Shares (millions): 1.3
Price range $12.00 - $14.00
Est. $ Volume $16.3 mil
Manager / Joint Managers Aegis Capital
CO-Managers -
Expected To Trade:
Status: TBA
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change